ArticleEClinicalMedicine2025
Impact of platinum-based chemotherapy and CTLA-4 inhibition on acquired resistance to first-line anti-PD-1/PD-L1 agents in non-small cell lung cancer: a systematic review and reconstructed individual patient data analysis.
Article in EClinicalMedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The role of the WD40-repeat protein family in cancer.Molecular cancer · 2026Review
- A Circulating Signature of Tumour Hybrid Cells and Immune Checkpoints Predicts Metastatic Progression in Lung Cancer.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acquired resistance is defined as disease progression following an initial response to immune checkpoint inhibitors (ICI). The impact of adding platinum-based chemotherapy (PCT) or anti-CTLA-4 agents to PD-(L)-1 inhibitors on acquired resistance is currently unknown. Methods: Systematic research by January 31, 2025 identified randomized clinical trials (RCTs) evaluating first-line ICI as monotherapy (mono-ICI) or in combination with PCT (mono-ICI + PCT), CTLA-4 inhibitors (combo-ICI), or both (combo-ICI + PCT) in metastatic non-small-cell lung cancer (NSCLC). RCTs reporting duration of response (DoR) data were eligible. Acquired resistance rates at 6 and 12 months were estimated from DoR curves. Aggregate data based on type of regimens were reported with risk ratio (RR) and pooled by random effect model. Primary and secondary endpoints were respectively the indirect comparison of acquired resistance risk between PCT-containing versus PCT-free regimens and between anti-CTLA-4 containing versus anti-CTLA-4 free regimens, respectively. Time-to-event outcomes were retrieved from Kaplan-Meier (KM) curves using individual patient data (IPD) and compared by log rank tests. This study was registered to the PROSPERO online platform (CRD42025639320). Findings: Nineteen RCTs were included. 6- and 12-months acquired resistance rates were 16.5%-34.1% (mono-ICI), 26.4%-47.8% (mono-ICI + PCT), 19.0%-33.0% (combo-ICI), and 28.4%-47.1% (combo-ICI + PCT). A higher risk of acquired resistance was suggested from indirect comparisons of mono-ICI + PCT versus mono-ICI (12-months RR: 1.46, 95% CI 1.23-1.75) and of combo-ICI + PCT versus combo-ICI (12 months RR: 1.36, 95% CI 1.06-1.73). Using the reconstructed patient-level data, median DoR was 5-7 months significantly shorter with PCT-containing compared to PCT-free regimens. The addition of anti-CTLA-4 agents did not impact on acquired resistance. Interpretation: Although insufficient RCTs reported acquired resistance rates stratified by specific factors influencing DoR (i.e., PD-L1, TMB) for such analyses to be included in this report, the increased acquired resistance risk observed with PCT-containing regimens highlights the potential value of tailoring first-line treatment strategies in NSCLC on the basis of individual risk of resistance to ICI. Funding: This research did not receive any specific grant from funding agencies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.